A Study of Suvecaltamide in Adults With Moderate to Severe Residual Tremor in Parkinson's Disease
Public ClinicalTrials.gov record NCT05642442. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 17-week, Phase 2, Randomized, Double-blind, Placebo-controlled, Flexible-dosing, Parallel-group, Multicenter Study of the Efficacy and Safety of Suvecaltamide in the Treatment of Moderate to Severe Residual Tremor in Participants With Parkinson's Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a 17-week double-blind, placebo-controlled, randomized, flexible-dosing, parallel-group, multicenter study designed to evaluate the efficacy and safety of suvecaltamide for the treatment of moderate to severe residual tremor in adult participants with Parkinson's disease (PD). The target population represents participants who have tremor that is not adequately controlled by PD medications and that interferes with their activities of daily living (ADL) and/or with their performance of tasks.
Study identification
- NCT ID
- NCT05642442
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 169 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 40 Years to 85 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 1, 2022 (Actual)
- Primary completion
- Oct 23, 2024 (Actual)
- Completion
- Nov 11, 2024 (Actual)
- Last update posted
- Jan 15, 2026
2022 – 2024
United States locations
- U.S. sites
- 21
- U.S. states
- 15
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Movement Disorders Center of Arizona | Scottsdale | Arizona | 85258 | — |
| Keck School of Medicine of University of Southern California (USC) | Los Angeles | California | 90033 | — |
| University of Colorado Hospital Anschutz Outpatient Pavilion | Aurora | Colorado | 80045 | — |
| Neurology of Central Florida Research Center LLC | Altamonte Springs | Florida | 32714 | — |
| Parkinson's Disease and Movement Disorder Center of Boca Raton | Boca Raton | Florida | 33486 | — |
| Clinical Neuroscience Solutions, Inc. | Jacksonville | Florida | 32256 | — |
| USF Parkinson's Disease and Movement Disorders Center | Tampa | Florida | 33613 | — |
| NeuroTrials Research Inc. | Atlanta | Georgia | 30328 | — |
| Hawaii Pacific Health | Honolulu | Hawaii | 96817 | — |
| Northwestern Medical Group, Department of Neurology | Chicago | Illinois | 60611 | — |
| University of Kansas Medical Center | Kansas City | Kansas | 66160 | — |
| University of Kentucky, College of Medicine, Department of Neurology | Lexington | Kentucky | 40536 | — |
| The Nene and Jamie Koch Comprehensive Movement Disorders Center | Albuquerque | New Mexico | 87106 | — |
| Albany Medical College | Albany | New York | 12208 | — |
| Dent Neurologic Institute | Amherst | New York | 14226 | — |
| Columbia University Irving Medical Center | New York | New York | 10032 | — |
| South Shore Neurologic Associates PC | Patchogue | New York | 11772 | — |
| University of Cincinnati Gardner Neuroscience Institute (UCGNI) | Cincinnati | Ohio | 45219 | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232 | — |
| Central Texas Neurology Consultants | Round Rock | Texas | 78681 | — |
| EverGreenHealth Neuroscience Institute | Kirkland | Washington | 98034 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05642442, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 15, 2026 · Synced Oct 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05642442 live on ClinicalTrials.gov.